Kayfanda (Odevixibat)

Odevixibat is employed in the management of cholestatic liver diseases, particularly in children, by inhibiting the ileal bile acid transporter and thereby reducing enterohepatic bile acid recirculation.

• Progressive familial intrahepatic cholestasis type 2 (PFIC2): reduces serum bile acid concentrations and improves liver biochemistry, potentially delaying disease progression.
• Alagille syndrome: decreases cholestasis, alleviates pruritus, and supports hepatic function in affected children.
• Pediatric cholestasis associated with PFIC or Alagille syndrome: helps control itching and may improve growth parameters.
• Bile acid–related pruritus in cholestatic conditions: may reduce itching severity and improve patient comfort.

• Odevixibat selectively inhibits the ileal bile acid transporter (IBAT), also known as the apical sodium‑dependent bile acid transporter (ASBT), located on the enterocytes of the distal ileum. By blocking this transporter, the drug prevents reabsorption of bile acids from the intestinal lumen, leading to increased fecal excretion and reduced enterohepatic circulation. The consequent lowering of systemic bile acid concentrations alleviates cholestatic injury in the liver.

Odevixibat may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

• Diarrhea: frequent loose stools that may affect hydration.
• Abdominal pain: mild to moderate discomfort in the stomach area.
• Fatigue: feeling unusually tired or low in energy.
• Elevated liver enzymes: mild increases in ALT or AST observed in labs.
• Nausea: occasional feeling of sickness or urge to vomit.

Serious or Rare Side Effects

• Severe liver injury: marked elevation of bilirubin or hepatic failure.
• Biliary obstruction: blockage of bile flow leading to jaundice.
• Acute pancreatitis: sudden inflammation of the pancreas with abdominal pain.
• Severe dehydration: significant fluid loss requiring medical attention.
• Allergic reaction: rash, itching, or swelling that may require discontinuation.

When prescribing Odevixibat, several precautionary measures should be observed to ensure patient safety.

• Liver function monitoring: regularly assess ALT, AST, and bilirubin levels.
• Pruritus assessment: evaluate severity of itching and adjust therapy as needed.
• Intestinal disease caution: use carefully in patients with inflammatory bowel disease or malabsorption.
• Hepatic impairment adjustment: consider dose modification in moderate to severe liver dysfunction.
• Allergy screening: avoid in individuals with known hypersensitivity to Odevixibat or excipients.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Odevixibat can interact with other medicines, affecting its absorption or efficacy.

Major Interactions (Avoid)

• Bile acid sequestrants (e.g., cholestyramine): may bind Odevixibat and reduce its oral absorption.
• Strong CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations of Odevixibat.
• Antacids containing aluminum or magnesium: may interfere with Odevixibat uptake in the gut.
• Fatty meals: high‑fat food may delay absorption, consider dosing on empty stomach.

Moderate Interactions (Monitor Closely)

• Oral antibiotics altering gut microbiota: may change bile acid pool and affect Odevixibat efficacy.
• Concurrent use of other IBAT inhibitors: additive inhibition may increase risk of diarrhea.
• Vitamin D supplements: may affect calcium metabolism when bile acid absorption is reduced; monitor levels.